Suppr超能文献

实践中的价值医疗:IDEATE,一项为威尔士一种药物设计并测试基于结果的协议的合作。

Value-Based Healthcare in Practice: IDEATE, a Collaboration to Design and Test an Outcomes-Based Agreement for a Medicine in Wales.

作者信息

Burton Jessica R, Halsby Kate, de la Fuente Graciela Sáinz, Pearson-Stuttard Jonathan, Sloan Rebecca, Porter Thomas, John Gareth, Warburton Andrew, Selby Jennifer, Povey Gail, Chowdhury Ruhe, Bale Catherine, Davies Mark, Clifton-Brown Emma, Laing Hamish

机构信息

UK Health and Value, Outcomes Innovation and Evidence, Pfizer Ltd, Walton Oaks, Tadworth, UK.

Division of Biosciences, University College London, London, UK.

出版信息

Pharmacoeconomics. 2025 Feb;43(2):191-207. doi: 10.1007/s40273-024-01445-0. Epub 2024 Nov 11.

Abstract

OBJECTIVE

To develop a sustainable, scalable methodology for the design of outcome-based agreements (OBAs) that works on the ground and dynamically overcomes historical challenges.

METHODS

Project IDEATE co-created solutions to known (and emergent) challenges via iterative workshops and real-world data analysis to develop and refine a hypothetical model for an OBA in a trusted research environment. A cross-disciplinary collaboration between National Health Service (NHS) Wales, industry and academia was developed. Data were collected from Welsh national datasets and used to construct a novel linked dataset. OBA scenarios, with different contract parameters, were analysed to assess impact on the proportion of contract payment due and the volatility of payments.

RESULTS

An approved, in market, locally advanced and metastatic breast cancer treatment was selected as the test case. The total number of patients in the treatment cohort (2017-2020) was n = 99, and 286 in the control cohort (2014-2016). The final outcome variables selected were: (1) 1-year survival,( 2) intolerance to treatment (deferral), and (3) the total days disrupted by care. The primary scenario included all three outcomes measured at the population level and used a linear payment model. Volatility analyses demonstrated contract parameters can dramatically alter the contract output with greatest risk from a single, binary outcome contract design.

CONCLUSIONS

The design of an OBA is a complex process that requires a multi-disciplinary approach. By assessing solutions to data, outcomes and contracting challenges, IDEATE provides a strong foundation for future success of OBAs in the UK. Outcome-based agreements (OBAs) are a way to pay for medicines if they help patient health in a specific way over time. These agreements can make it faster for people to get new medicines, but they also have challenges, like needing a lot of time and effort to manage them. A team from the NHS Wales, life sciences, and Swansea University created Project IDEATE to find a better way to design OBAs and solve some of these problems. Welsh datasets were used to create a new breast cancer dataset to test different OBAs and see how payments would change. A breast cancer treatment was used for the project. The project had 99 patients who got the medicine (2017-2020) and 286 patients who had breast cancer but did not get the medicine (2014-2016). Three health outcomes were measured: (1) living for one year after treatment, (2) patients needing to stop the medicine, and (3) days spent in care. The main OBA option we tested used all three health outcomes; the more the outcomes improved, the more the payments could go up until they hit the highest amount agreed. The analysis showed that the way an OBA is designed can make a big difference in how stable or risky it is, especially if one of the health outcomes has only two options. Project IDEATE showed that making an OBA can be hard, but when people from different fields work together, they can overcome many challenges and succeed.

摘要

目的

开发一种可持续、可扩展的方法,用于设计基于结果的协议(OBA),该方法能够在实际中发挥作用,并动态克服历史挑战。

方法

IDEATE项目通过迭代研讨会和实际数据分析,共同创建了针对已知(和新出现)挑战的解决方案,以在可信的研究环境中开发和完善OBA的假设模型。开展了英国国家医疗服务体系(NHS)威尔士分部、行业和学术界之间的跨学科合作。从威尔士国家数据集收集数据,并用于构建一个新的链接数据集。对具有不同合同参数的OBA情景进行分析,以评估对到期合同付款比例和付款波动性的影响。

结果

选择一种已获批、在市场上销售、用于局部晚期和转移性乳腺癌的治疗药物作为测试案例。治疗队列(2017 - 2020年)中的患者总数为n = 99例,对照队列(2014 - 2016年)中有286例。最终选定的结果变量为:(1)1年生存率,(2)治疗不耐受(延期),以及(3)因护理而中断的总天数。主要情景包括在人群层面测量的所有三个结果,并使用线性支付模型。波动性分析表明,合同参数可显著改变合同产出,单一二元结果合同设计带来的风险最大。

结论

OBA的设计是一个复杂的过程,需要多学科方法。通过评估针对数据、结果和合同挑战的解决方案,IDEATE为英国OBA未来的成功奠定了坚实基础。基于结果的协议(OBA)是一种支付药品费用的方式,前提是这些药品能在一段时间内以特定方式改善患者健康。这些协议可以让人们更快地获得新药,但也存在挑战,比如需要大量时间和精力来管理。威尔士NHS、生命科学领域以及斯旺西大学的一个团队创建了IDEATE项目,以找到更好的设计OBA的方法并解决其中一些问题。威尔士数据集被用于创建一个新的乳腺癌数据集,以测试不同的OBA并观察付款情况如何变化。该项目使用了一种乳腺癌治疗药物。该项目有99名接受该药物治疗的患者(2017 - 2020年)和286名患有乳腺癌但未接受该药物治疗的患者(2014 - 2016年)。测量了三个健康结果:(1)治疗后存活一年,(2)患者需要停药,以及(3)护理天数。我们测试的主要OBA方案使用了所有三个健康结果;结果改善得越多,付款增加得就越多,直到达到商定的最高金额。分析表明,OBA的设计方式对其稳定性或风险有很大影响,特别是如果其中一个健康结果只有两种选择。IDEATE项目表明,制定OBA可能很困难,但当不同领域的人共同努力时,他们可以克服许多挑战并取得成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11fb/11782430/221b646947c2/40273_2024_1445_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验